Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Authors
Keywords
-
Journal
Journal of Diabetes Research
Volume 2019, Issue -, Pages 1-12
Publisher
Hindawi Limited
Online
2019-03-04
DOI
10.1155/2019/1365162
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis
- (2018) Raffaele Marfella et al. Diabetology & Metabolic Syndrome
- Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate
- (2018) Celestino Sardu et al. Cardiovascular Diabetology
- Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice
- (2017) Andreas Lindqvist et al. Frontiers in Endocrinology
- Exendin-4 decreases ghrelin levels through mTOR signaling
- (2016) Xiaosi Hong et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes
- (2015) Angus G. Jones et al. DIABETES CARE
- Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation
- (2015) Liselotte van Bloemendaal et al. Obesity
- The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
- (2015) Stefanie Amarens de Boer et al. International Journal of Clinical Pharmacy
- Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
- (2015) Muhammad Khan et al. Journal of Diabetes Research
- Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents
- (2014) Ronald M. Goldenberg Canadian Journal of Diabetes
- Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment
- (2014) Maria Luisa Balestrieri et al. DIABETES
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers
- (2014) Eren Gurkan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
- (2014) E W Iepsen et al. INTERNATIONAL JOURNAL OF OBESITY
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in Obese Mice Chronically Maintained on an Obesogenic Diet
- (2013) C. Clemmensen et al. DIABETES
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Impact of Diabetes on Cardiovascular Disease: An Update
- (2013) Alessandra Saldanha de Mattos Matheus et al. International Journal of Hypertension
- Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Glucagon-Like Peptide-1 Receptor Agonist, Exendin-4, Regulates Feeding-Associated Neuropeptides in Hypothalamic Neuronsin Vivoandin Vitro
- (2012) Prasad S. Dalvi et al. ENDOCRINOLOGY
- Fasting and Meal-Induced CCK and PP Secretion Following Intragastric Balloon Treatment for Obesity
- (2012) Elisabeth M. H. Mathus-Vliegen et al. OBESITY SURGERY
- GLP-1 receptor agonists and HBA1ctarget of
- (2011) K. Esposito et al. CURRENT MEDICAL RESEARCH AND OPINION
- Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
- (2011) J. Dushay et al. DIABETES CARE
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Weight Regain after a Diet-Induced Loss Is Predicted by Higher Baseline Leptin and Lower Ghrelin Plasma Levels
- (2010) Ana B. Crujeiras et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now